Cargando…
2273. Outcomes of Trimethoprim/Sulfamethoxazole as Definitive Therapy for Urinary Tract Infections with Multi-Drug-Resistant Enterobacteriaceae
BACKGROUND: Trimethoprim/Sulfamethoxazole (TMP/SMX) is not routinely employed for urinary tract infections (UTI) with multi-drug-resistant organisms (MDRO) due to paucity of effectiveness data, concerns regarding inadequate urinary penetration, and risk of adverse effects. We describe our experience...
Autores principales: | Adhi, Fatima, Dubrovskaya, Yanina, Cytryn, Samuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810461/ http://dx.doi.org/10.1093/ofid/ofz360.1951 |
Ejemplares similares
-
The rates of quinolone, trimethoprim/sulfamethoxazole and aminoglycoside resistance among Enterobacteriaceae isolated from urinary tract infections in Azerbaijan, Iran
por: Yekani, Mina, et al.
Publicado: (2018) -
The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Luterbach, Courtney L, et al.
Publicado: (2018) -
1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018) -
Fixed Drug Eruption to Trimethoprim-Sulfamethoxazole and Doxycycline
por: Long, Clara Y, et al.
Publicado: (2021) -
Sulfamethoxazole-Trimethoprim and Hyperkalemia in an Infant
por: Hudzik, Samantha A., et al.
Publicado: (2020)